Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Non-Current Deffered Revenue (2020 - 2025)

Historic Non-Current Deffered Revenue for IDEAYA Biosciences (IDYA) over the last 4 years, with Q3 2025 value amounting to $1.7 million.

  • IDEAYA Biosciences' Non-Current Deffered Revenue changed N/A to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $5.2 million for FY2022, which is 8337.71% down from last year.
  • As of Q3 2025, IDEAYA Biosciences' Non-Current Deffered Revenue stood at $1.7 million.
  • IDEAYA Biosciences' 5-year Non-Current Deffered Revenue high stood at $52.1 million for Q1 2021, and its period low was $1.7 million during Q3 2025.
  • In the last 3 years, IDEAYA Biosciences' Non-Current Deffered Revenue had a median value of $10.2 million in 2022 and averaged $22.5 million.
  • As far as peak fluctuations go, IDEAYA Biosciences' Non-Current Deffered Revenue crashed by 1502.19% in 2021, and later plummeted by 8337.71% in 2022.
  • Quarter analysis of 3 years shows IDEAYA Biosciences' Non-Current Deffered Revenue stood at $31.2 million in 2021, then tumbled by 83.38% to $5.2 million in 2022, then tumbled by 67.68% to $1.7 million in 2025.
  • Its Non-Current Deffered Revenue was $1.7 million in Q3 2025, compared to $5.2 million in Q4 2022 and $7.3 million in Q3 2022.